For a long time, pharma companies have looked to large disease populations as the biggest potential revenue streams. But those days are long gone. That perception has shifted, especially with the prescription drug market stagnating in the U.S. and Europe. Orphan drugs--pharmaceutical treatments for rare diseases or disorders--have proven themselves as viable moneymakers, and the industry has taken note. Read the report >>
Biogen Idec's ($BIIB) newly approved Tecfidera has a wholesale price of $54,900 per year, the biotech giant revealed on Friday. With the U.S. market debut of the oral multiple sclerosis drug set for Monday, Biogen plans to hit the market for MS pills with a lower price than Novartis' ($NVS) Gilenya, which is arguably the company's top competition.
Biogen Idec reported that its candidate peginterferon beta-1a, a long-lasting version of its blockbuster Avonex, reduced relapse rates in multiple sclerosis patients.
The Department of Defense has awarded a one-year grant to SRI International's bioscience division to develop an orally administered multiple sclerosis drug.
Biogen Idec ($BIIB) gained the FDA's go-ahead this week for a drug delivery advance and dosing change intended to improve how MS patients take Avonex. They are subtle yet significant ways...
Biogen Idec ($BIIB) is taking its multiple sclerosis marketing in-house. The Massachusetts-based company has bought out the joint-venture partner that had been selling Avonex and Tysabri, forming
We've heard a lot about Novartis' new multiple sclerosis drug Gilenya, the first oral treatment for the disease. It has hit the ground running, growing sales and grabbing market share just as the
Biogen Idec has succeeded in extending patent protection for its multiple sclerosis drug Avonex to 2026, some 13 years beyond the original patent-expiration date. The IP sleight of hand comes in the
Biogen Idec rolled out the red carpet to analysts and journalists alike yesterday as it touted its research program and talked up its mid- and late-stage drug prospects. The Boston-based company,